Results 101 to 110 of about 103,990 (261)
Low vision intervention in end-stage corneal disease. [PDF]
Natarajan R +3 more
europepmc +1 more source
ABSTRACT The objective was to prepare guidelines to perform the current optimum treatment by organizing effective and efficient treatments of hemangiomas and vascular malformations, confirming the safety, and systematizing treatment, employing evidence‐based medicine techniques and aimed at improvement of the outcomes.
Yoshiaki Kinoshita +116 more
wiley +1 more source
Corneal biomechanical cues mediated by PAI-2: the origin of PM2.5-induced corneal disease. [PDF]
Hao S +20 more
europepmc +1 more source
ABSTRACT Baricitinib and ritlecitinib are newly approved systemic Janus kinase (JAK) inhibitors for severe, refractory alopecia areata (AA). Although clinical trials have demonstrated their efficacy, real‐world evidence remains limited, particularly regarding predictors of response and outcomes following treatment interruption or dose tapering.
Rina Hayashi +2 more
wiley +1 more source
Diagnostic Performance of ChatGPT in Corneal Disease Recognition From Slit-Lamp Photographs. [PDF]
Khan MA, Baker D.
europepmc +1 more source
Capabilities of Gabor-domain optical coherence microscopy for the assessment of corneal disease. [PDF]
Tankam P +8 more
europepmc +1 more source
Abstract Objective Medical devices are reviewed by the US Food and Drug Administration (FDA) for safety and effectiveness. Class II devices can receive 510(k) clearance if they are “substantially equivalent” to an existing predicate device. This process can be repeated iteratively, leading to a lineage of predicates for newly cleared devices.
Yiting Lin +3 more
wiley +1 more source

